Advertisement

Topics

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018 [Report Updated: 18092018] Prices from USD $2500

09:38 EST 10 Jan 2019 | BioPortfolio Reports

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018


Summary


This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.


Questions topics

Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial

Views on the Phase III safety data for abatacept in LN

Expectations regarding abatacept's future development in lupus

Opinion on ustekinumab's ability to achieve partial improvements using SLEDAI2K Responder Index50

Views on ustekinumab's Phase III trial design

Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE

Perception of etanercept's efficacy in discoid lupus erythematosus

Opinion on etanercept's safety data from the Phase II TARGETDLE trial


Key Highlights


While most KOLs agreed that abatacept's future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis

Most KOLs highlighted that SLEDAI2K Responder Index50 data supports ustekinumab use in SLE

While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders KOLs.


In total, we conducted interviews with 10 KOLs

5 Europebased 5 N. Americabased

Interviews performed during Aug 2018


KOL data is analyzed to produce

Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of Lupus

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018 [Report Updated: 18092018] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018 [Report Updated: 18092018] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...